← All trials
NCT06279793
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Feb 28, 2024
- Last posted
- Sep 23, 2024
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GCP-Service International Ltd. & Co. KGLead sponsor
- Humboldt UniversityCollaborator
- Julius-Maximilians UniversityCollaborator
- University of GoettingenCollaborator
- Universitaetsklinikum Schleswig-HolsteinCollaborator
- University of MunsterCollaborator
- University of BonnCollaborator
- University of HamburgCollaborator
- Julius-Maximilians UniversityOfficial
- Johannes Gutenburg UniversityCollaborator
- University of AugsburgCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.